Celldex Therapeutics’ (CLDX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report released on Thursday,Benzinga reports. They currently have a $80.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on CLDX. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Monday, September 16th. The Goldman Sachs Group began coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They set a “neutral” rating and a $45.00 price target for the company. Wolfe Research lowered shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. Finally, Citigroup started coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Price Performance

Shares of CLDX stock opened at $26.22 on Thursday. The business’s 50-day moving average price is $33.60 and its 200-day moving average price is $35.82. Celldex Therapeutics has a 12 month low of $24.43 and a 12 month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. The company had revenue of $2.50 million for the quarter, compared to analyst estimates of $1.13 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. Analysts predict that Celldex Therapeutics will post -2.5 earnings per share for the current year.

Institutional Trading of Celldex Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLDX. Vanguard Group Inc. grew its stake in Celldex Therapeutics by 19.8% in the first quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock valued at $153,215,000 after acquiring an additional 604,251 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Celldex Therapeutics by 631.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock valued at $129,571,000 after purchasing an additional 2,664,915 shares in the last quarter. Bellevue Group AG increased its stake in Celldex Therapeutics by 15.7% during the 1st quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company’s stock valued at $117,374,000 after purchasing an additional 380,319 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in Celldex Therapeutics by 51.0% during the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock worth $71,725,000 after buying an additional 654,194 shares during the last quarter. Finally, Marshall Wace LLP lifted its stake in shares of Celldex Therapeutics by 53.3% in the second quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock valued at $50,995,000 after buying an additional 479,068 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.